Literature DB >> 17064291

Histological assessment of non-alcoholic fatty liver disease.

S G Hübscher1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an important complication of the metabolic syndrome, which is becoming an increasingly common cause of chronic liver disease. Histological changes typically mainly affect perivenular regions of the liver parenchyma and include an overlapping spectrum of steatosis, steatohepatitis and persinusoidal or pericellular fibrosis, in some cases leading to cirrhosis. Once cirrhosis has developed, typical hepatocellular changes are often no longer conspicuous, leading to such cases being mistakenly diagnosed as 'cryptogenic'. Portal inflammation, ductular reaction and periportal fibrosis can also be seen as part of the morphological spectrum of NAFLD, particularly in the paediatric population. Hepatocellular carcinoma has also been described as a complication of NAFLD-associated cirrhosis. NAFLD is also an important cofactor in other chronic liver diseases, especially hepatitis C. Histological assessments have an important role to play in the diagnosis and management of NAFLD. These include making the potentially important distinction between simple steatosis and steatohepatitis and providing pointers to the aetiology, including cases where a dual pathology exists. A number of systems have been devised for grading and staging the severity of fatty liver disease. These require further evaluation, but have a potentially important role to play in determining prognosis and monitoring therapeutic responses.

Entities:  

Mesh:

Year:  2006        PMID: 17064291     DOI: 10.1111/j.1365-2559.2006.02416.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  93 in total

1.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

Review 2.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

4.  Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease.

Authors:  Benjamin Wolfson; Pang-Kuo Lo; Yuan Yao; Linhao Li; Hongbing Wang; Qun Zhou
Journal:  Mol Nutr Food Res       Date:  2018-06-12       Impact factor: 5.914

5.  Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.

Authors:  Wen Liang; Jan H Lindeman; Aswin L Menke; Debby P Koonen; Martine Morrison; Louis M Havekes; Anita M van den Hoek; Robert Kleemann
Journal:  Lab Invest       Date:  2014-02-24       Impact factor: 5.662

6.  MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients.

Authors:  Milan Hájek; Monika Dezortová; Dita Wagnerová; Antonín Skoch; Luděk Voska; Irena Hejlová; Pavel Trunečka
Journal:  MAGMA       Date:  2011-07-10       Impact factor: 2.310

7.  Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.

Authors:  Wantae Kim; Sanjoy Kumar Khan; Jelena Gvozdenovic-Jeremic; Youngeun Kim; Jason Dahlman; Hanjun Kim; Ogyi Park; Tohru Ishitani; Eek-Hoon Jho; Bin Gao; Yingzi Yang
Journal:  J Clin Invest       Date:  2016-11-21       Impact factor: 14.808

8.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction.

Authors:  Long Wang; Yisong Lv; Huixiang Yao; Li Yin; Jianhui Shang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity.

Authors:  Jean O'Connell; Lydia Lynch; Tom J Cawood; Anna Kwasnik; Niamh Nolan; Justin Geoghegan; Aiden McCormick; Cliona O'Farrelly; Donal O'Shea
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.